Please use this identifier to cite or link to this item:
https://dipositint.ub.edu/dspace/handle/2445/208137
Title: | Sustained inhibition of calcineurin activity with a Melt‐Dose Once‐daily Tacrolimus formulation in renal transplant recipients |
Author: | Montero Pérez, Núria Fontova, Pere Colom Codina, Helena Rigo Bonnin, Raúl Bestard Matamoros, Oriol Vidal Alabró, Anna van Merendonk, Lisanne Cerezo, Gema Polo, Carolina Melilli, Edoardo Manonelles, Anna Meneghini, Maria Coloma, Ana Cruzado, Josep Ma. Torras Ambròs, Joan Grinyó Boira, Josep M. Lloberas Blanch, Núria |
Keywords: | Immunosupressors Trasplantament renal Cromatografia Immunosupressive agents Kidney transplantation Chromatography |
Issue Date: | 24-Feb-2021 |
Publisher: | John Wiley & Sons |
Abstract: | Tacrolimus (Tac) is the cornerstone calcineurin inhibitor in transplantation. Extended-release Meltdose formulation (Tac-LCP) offers better bioavailability compared with immediate-release formulation (Tac-IR). We postulated that the less fluctuating pharmacokinetic (PK) profile of Tac-LCP might maintain a sustained inhibition of calcineurin activity (CNA) between dose intervals. Higher concentrations (peak plasma concentration (Cmax )) after Tac-IR may not result in a more potent CNA inhibition due to a capacity-limited effect. This study was aimed at evaluating the pharmacodynamic (PD)/PK profiles of Tac-IR compared with Tac-LCP. An open-label, prospective, nonrandomized, investigator-driven study was conducted. Twenty-five kidney transplant recipients receiving Tac-IR were switched to Tac-LCP. Before and 28 days after conversion, intensive CNA-PD and PK sampling were conducted using ultra-high-performance liquid chromatography-tandem accurate mass spectrometry. PD nonlinear mixed effects model was performed in Phoenix-WinNonlin. Statistically significant higher Cmax (P < 0.001) after Tac-IR did not result in lower CNA as compared with after Tac-LCP (P = 0.860). Tac-LCP showed a statistically more maintained CNA inhibition between dose intervals (area under the effect-time curve from 0 to 24 hours (AUE0-24h )) compared with Tac-IR, in which CNA returned to predose levels after 4 hours of drug intake (373.8 vs. 290.5 pmol RII·h/min·mg prot, Tac-LCP vs. Tac-IR; P = 0.039). No correlation was achieved between any PD and PK parameters in any formulations. Moreover, Tac concentration to elicit a 50% of the maximum response (half-maximal inhibitory concentration) was 9.24 ng/mL. The higher Cmax after Tac-IR does not result in an additional CNA inhibition compared with Tac-LCP attributable to a capacity-limited effect. Tac-LCP may represent an improvement of the PD of Tac due to the more sustained CNA inhibition during dose intervals. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1002/cpt.2220 |
It is part of: | Clinical Pharmacology & Therapeutics, 2021, vol. 110, num.1, p. 238-247 |
URI: | http://hdl.handle.net/2445/208137 |
Related resource: | https://doi.org/10.1002/cpt.2220 |
ISSN: | 0009-9236 |
Appears in Collections: | Articles publicats en revistes (Infermeria Fonamental i Clínica) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
238820.pdf | 796.49 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.